港股異動 | 券商唱好 和鉑醫藥-B(02142.HK)一度漲超8%
格隆匯4月19日丨和鉑醫藥-B(02142.HK)盤初一度急漲超8%,現報3.87港元,暫成交1679萬港元,總市值30.1億港元。中信建投指出,公司擁有全球領先三大稀缺性核心技術平台、卓越研發能力以及高度差異化、創新性研發管線,同時考慮到HBM7022對外授權獲得首付款及潛在里程碑收入和銷售額特許權使用費分成,預計2025年公司實現盈虧平衡,首次覆蓋,給予“買入”評級。另外,在4月7日,公司與阿斯利康簽訂CLDN18.2xCD3雙抗(HBM7022)授權協議。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.